Orforglipron vs Retatrutide

The orforglipron vs retatrutide decision is a choice between an FDA-approved daily pill and a still-investigational weekly triple-agonist injection. Foundayo offers regulated access now; retatrutide produced the larger phase 3 weight-loss number. No trial has compared them directly, so this page weighs separate studies and gives picks by goal, not a universal winner.

What is the core difference between orforglipron and retatrutide?

Orforglipron is the convenience-first branch of Lilly’s obesity pipeline; retatrutide is the multi-receptor branch built to push efficacy further. Orforglipron is a non-peptide small molecule that activates only the GLP-1 receptor and survives digestion as a tablet. Retatrutide is a peptide injection that activates GLP-1, GIP and glucagon receptors with one molecule.

That makes the oral GLP-1 vs triple agonist question more than pill versus needle. GLP-1 and GIP signaling can reduce appetite and support glucose-dependent insulin release. Retatrutide adds glucagon-receptor activity, which may increase energy expenditure and fat oxidation. The extra pathway is a plausible reason for its larger trial numbers, but mechanism alone never proves a better outcome for a particular person.

The schedule also flips: Foundayo is taken every day, while retatrutide was tested once weekly. Some people would rather remember one tablet each morning; others would rather deal with one injection a week. Convenience is personal. Regulatory status is not.

Does retatrutide cause more weight loss than Foundayo?

Retatrutide posted the larger average in separate phase 3 trials, but no direct trial has tested Foundayo vs retatrutide. ATTAIN-1 reported 11.1% average loss at 72 weeks with the highest orforglipron dose when participants were counted regardless of treatment completion. TRIUMPH-1 reported 28.3% at 80 weeks with 12 mg retatrutide under an efficacy estimand. Those numbers answer two different trial questions.

Cross-trial comparisons can mislead because the studies differed in duration, participants, dose escalation and how missing data or treatment discontinuation were handled. Even the orforglipron headline changes with the statistical lens: Lilly reported 12.4% among the modeled scenario in which randomized participants remained on treatment, versus 11.1% regardless of adherence or prohibited rescue treatment. Retatrutide’s 28.3% headline also uses an efficacy estimand. A clean leaderboard would require the same protocol and randomization between the two drugs. That study does not exist.

Both compounds still deserve the Human RCT evidence badge. The honest distinction is maturity: orforglipron’s evidence package passed FDA review, while retatrutide’s phase 3 program is still feeding a future application.

What is the retatrutide approval date?

Retatrutide has no approval date because the FDA has not approved it or received a publicly confirmed approved application. Lilly’s June 2026 investor material places potential obesity, osteoarthritis and sleep-apnea submissions in the second half of 2026. That supports the common Q4 2026 expectation, but it does not turn Q4 into a filed date or guarantee a decision.

The earliest plausible approval is therefore 2027. A 2027-28 window is a forecast, not a deadline set by FDA. Reviews can move faster, slip, request more data or end without approval. Anyone quoting a precise retatrutide approval date today is filling in a blank the regulator has not filled.

Orforglipron has crossed that line. FDA approved Foundayo on April 1, 2026 for chronic weight management in adults with obesity, or overweight plus at least one weight-related condition. That status gap is the main answer when these Lilly obesity drugs are compared in July 2026.

Can people buy retatrutide legally now?

Retatrutide is not an approved retail medicine, and online vials sold to consumers are gray-market products rather than Lilly’s clinical-trial drug. FDA says retatrutide cannot qualify for federal 503A or 503B compounding exemptions and has warned sellers using labels such as “research purposes” while marketing for human use. Unknown purity and dose are supply-chain risks on top of the drug’s biological risks.

Legitimate access can exist through registered trials and narrow FDA-authorized pathways, but that is not the same as an internet storefront. The gray-market peptide guide explains why a matching label does not establish identity, sterility or strength. The broader peptide legality guide separates possession, compounding, prescribing and lawful marketing instead of flattening them into one vague “legal” claim.

Foundayo is available by prescription through the regulated US drug supply. FDA reviewed its manufacturing, labeling, efficacy and safety package. Approval does not mean harmless: the label carries contraindications, warnings and the familiar gastrointestinal effects seen across GLP-1 drugs. It does mean the tablet in the package is the reviewed product. That is a meaningful difference from a vial whose contents depend on the seller’s word.

Which option fits which goal?

Orforglipron fits the goal of regulated access now, avoiding injections and using a product with an FDA-reviewed label. Retatrutide fits a different, future-facing goal: following the largest phase 3 average and preferring weekly dosing, if approval eventually arrives. Neither answer travels well without its condition attached.

The by-goal picks below keep availability separate from potential. Someone asking “what can be prescribed now?” gets Foundayo. Someone asking “which Lilly candidate set the higher phase 3 weight-loss mark?” gets retatrutide, followed immediately by the words separate trial and investigational. That is less satisfying than crowning a champion, but much more useful.

Orforglipron vs retatrutide is ultimately a status-gap story. The pill is the approved product with the smaller trial average. The triple agonist is the higher-number candidate without an approved supply chain. Retatrutide may become the stronger fit for some goals after FDA review; until then, potential and availability belong in different columns.